We designed an artificial liver support system (ALSS) including plasma exchange, charcoal hemoperfusion, plasma bilirubin absorption, charcoal plasma perfusion, hemofiltration and hemodialysis. We chose different methods or their combinations according to the patients’ conditions. We investigated the effect of ALSS in 154 patients with severe hepatitis, 72 of whom survived. All data were analyzed by SPSS. The effectiveness of ALSS treatment was compared at different stages (i.e. early, middle and end stages). After each ALSS treatment, the liver function of these patients greatly improved, serum endotoxin and HBV-DNA concentrations were significantly decreased, and the serum concentration of aromatic amino acids (AAA) such as methionine decreased while BCAA/AAA ratio increased. Patients treated with ALSS in the early or middle stages of disease had much higher survival rates than patients in the end stage of disease. Thus, we concluded that ALSS is a reliable therapy for advanced liver diseases and treatment in early or middle stages is appropriate.
OstapowiczG., LeeW.M.Acute hepatic failure: a western perspective.J Gastroenterol Hepatol2000; 15: 480–8.
4.
Van HoekB., De BoerJ., BoudjemaK.Auxiliary versus orthotopic liver transplantation for acute liver failure.EURALT Study Group. European Auxiliary Liver Transplant Registry. J Hepatol1999; 30: 699–705.
5.
MiwaS., HashikuraY., MitaA.Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure.Hepatology1999; 30: 1521–6.
6.
AmyL.Friedman.Why bioartificial liver support remains the holy grail. ASAIO J1998; 44: 241–3.
7.
AbounaG.M., GangulyP.K., HamdyH.M.Extracorporeal liver perfusion system for successful hepatic support pending liver regeneration or liver transplantation: a pre-clinical controlled trial.Transplantation1999; 67: 1576–83.
8.
UchinoJ., MatsushitaM.Artificial liver: strategies for the rescue of patients with liver failure.ASAIO J1994, 40: 74–7.
9.
TakahashiT., MalcheskyP.S., NoseY.Artificial liver: state of the art.Dig Dis Sci1991; 36: 1327–40.
10.
MarxU., BushnaqH., YalcinE.European research and commercialization activities in the field of tissue engineering and liver support in world wide competition.Int J Artif Organs1998; 21: 119–26.
NeuzilD.F., RozgaJ., MoscioniA.D.Use of a novel bioartificial liver in a patient with acute liver insufficiency.Surg1993; 113: 340–3.
13.
WatanabeF.D., MullonC.J., HewittW.R.Clinical experience with a bioartificial liver in the treatment of severe liver failure.A phase I clinical trial. Ann Surg1997; 225: 484–91.
14.
SiC.W., ZhangH., WangB.E.Prevention and cure project of viral hepatitis.Revised Statement 5th National Infectious Disease Meeting, Beijing, 1995. Chinese Journal of Infectious Disease1995; 13: 241–7.
15.
KatoA., SuzukiK., SatoS.Imbalance of amino acid metabolism in fulminant hepatitis and its management.Nippon Rinsho1992; 50: 1599–603.
16.
TakahashiY.Evaluation of the special therapies in fulminant viral hepatitis -a multi-institution study.Nippon Shokakibyo Gakkai Zasshi1995; 92: 7–18.
17.
HigashiT.Impaired metabolism of methionine in severe liver diseases: I.Clinical and pathophysiological significance of elevated serum methionine levels. Gastroenterol JPN1982; 17: 117–24.
18.
ToborekM., KopiecznaG.E., DrozdzM.Increased lipid peroxidation and antioxidant activity in methionine induced hepatitis in rabbits.Nutrition1996; 12: 534–7.
19.
GossJ.A., ShackletonC.R., MaggardM.Liver transplantation for fulminant hepatic failure in the pediatric patient.Arch Surg1998; 133: 839–46.
20.
EsquivelC.O., KeeffeE.B., GarciaG.Resection versus transplantation for hepatocellular carcinoma.J Gastroenterol Hepatol1999; 14 Suppl: S37–41.
21.
AgishT., NakagawaY., TerakokaS.Plasma exchange as a rescue strategy for hepatic failure.ASAIO J1994; 40: 77–9.
22.
LarsenF.S., HansenB.A., JorgensenL.G.Cerebral blood flow velocity during high volume plasmapheresis in fulminant hepatic failure.Int J Artif Organs1994; 17: 353–61.
